source
- BlossomHill Therapeutics targets $112 million IPO to fund EGFR lung-cancer drug BH-30643BlossomHill Therapeutics, a San Diego oncology biotech, announced plans for an initial public offering to raise about $112 million. The company intends to sell 7.8 million shares at $15-$17 each,…
- In-patient cardiac pre-hab program launched to keep heart-transplant candidates fit while awaiting surgeryPatients waiting in the hospital for a heart transplant often lose strength and can become ineligible for the procedure as their fitness declines. To address this, Dr. Radha Gopalan at Banner‑Univ…